We describe a unique case of various types of basal cell carcinoma (BCC) associated with basaloid follicular hamartoma (BFH) in a 56-year-old female patient. The lesion consisted of a dark brown and elastic soft nodule and papules within the area of a birthmark on the neck. The lesion was surgically excised. Histological examination of the nodular region revealed aggregations of neoplastic basaloid cells. We diagnosed the nodule as BCC with a racemiform or reticular pattern. In addition, a specimen taken from brownish black papules within the birthmark was found to be composed of anastomosing cords of basaloid cells accompanied by infundibular cystic structures. These features were consistent with an infundibulocystic BCC. In contrast, specimens from a hamartomatous plaque showed distinctive branching strands of basaloid cells that are suggestive of BFH. Therefore, our findings indicate that several types of BCC may develop within a BFH.

Keywords:
Follicular hamartoma, Infundibulocystic basal cell carcinoma, Adnexal neoplasm
1.
Brown AC, Crounse RG, Winkelmann RK: Generalized hair follicle hamartoma associated with alopecia, aminoaciduria and myasthenia gravis. Arch Dermatol 1969;99:478–493.
2.
Tozawa T, Ackerman AB: Basal cell carcinoma with follicular differentiation. Am J Dermatopathol 1987;9:474–482.
3.
Walsh N, Ackerman AB: Infundibulocystic basal cell carcinoma: A newly described variant. Mod Pathol 1990;3:599–608.
4.
Brownstein MH: Basaloid follicular hamartoma: Solitary and multiple types. J Am Acad Dermatol 1992;27:237–240.
5.
Walsh N, Ackerman AB: Basaloid follicular hamartoma: Solitary and multiple types (letter). J Am Acad Dermatol 1993;29:125–127.
6.
Brownstein MH: Reply to letter of Drs. Walsh and Ackerman (letter). J Am Acad Dermatol 1993;29:127–129.
7.
Jimenez-Acosta FJ, Redondo E, Baez O, Hernandez B: Linear unilateral basaloid follicular hamartoma. J Am Acad Dermatol 1992;27:216–319.
8.
Nelson BR, Johnson TM, Waldinger T, Gillard M, Lowe L: Basaloid follicular hamartoma: A histologic diagnosis with diverse clinical presentations. Arch Dermatol 1993;129:915–917.
9.
Barrett TL, Smith KJ, Williams J, Corner SW, Hodge JJ, Skelton HG: Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceous. Mod Pathol 1999;12:450–455.
10.
Naeyaert JM, Pauwels C, Geerts ML, Verplancke P: CD34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol 2001;28:538–541.
11.
Duan H, Koga T, Masuda T, Mashino T, Imafuku S, Terao H, Murakami Y, Urabe K, Kiryu H, Furue M: CD1a+, CD3+, CD4+, CD8+, CD68+ and cutaneous lymphocyte-associated antigen-positive cells in Bowen’s disease. Br J Dermatol 2000;143:1211–1216.
12.
Ridley CM, Smith N: Generalized hair follicle hamartoma associated with alopecia and myasthenia gravis: Report of a second case. Clin Exp Dermatol 1981;6:283–289.
13.
Mehregan AH, Baker S: Basaloid follicular hamartoma: Three cases with localized and systematized unilateral lesions. J Cutan Pathol 1985;12:55–65.
14.
Requena L, Farina MDC, Robledo M, Sangueza OP, Yus ES, Villanueva A, Marquina A, Tamarit R: Multiple hereditary infundibulocystic basal cell carcinomas: A genodermatosis different from nevoid basal cell carcinoma syndrome. Arch Dermatol 1999;135:1227–1235.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.